| Name | Title | Contact Details |
|---|
Techne Corporation , incorporated in Minnesota in 1981, is a holding company which has two wholly-owned operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) located in Minneapolis, Minnesota and R&D Systems Europe Ltd. (RDSE) located in Abingdon, England. Over 95% of TECHNE's revenues are derived from products developed and manufactured in-house. R&D Systems is a specialty manufacturer of biological products. It has two operating divisions: Hematology and Biotechnology. The Hematology Division develops and manufactures hematology controls, which are used in hospitals and clinical laboratories to check the accuracy of blood analysis instruments. The Biotechnology Division develops and manufactures biotechnology products including purified proteins (cytokines) and antibodies that are sold primarily to the research market, and assay kits which are sold to the research and clinical diagnostic markets. RDSE sells and distributes Techne's biotechnology products in Europe.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering
Accium BioSciences is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AgriThority® is the first independent data-through-delivery product and market development company in the agriculture industry. Instead of delivering a “data dump” and walking away, AgriThority® assimilates and summarizes data to ensure you get the consistency and continuity your project demands. Producers benefit, too. AgriThority® has unmatched strength in the development of best management practices (BMPs) in animal health, agronomic and horticultural crop production, and in the development of product use within those BMPs. AgriThority® further builds trust and credibility for products and innovations by providing and delivering training and educational programs for company sales and field development organizations, technical influencers, channel partners and producers.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.